skip to content

Office for Translational Research



The Office for Translational Research (OTR) works closely with the following organisations:

We liaise with leading researchers (PIs) within the University and hospital, industry partners, other universities, charities and several other public and private organisations, such as funders.


Our Stakeholders

Professor Ian Wilkinson 
Prof Wilkinson's research interests centre on the physiology and pharmacology of the cardiovascular system, and particularly hypertension, the large arteries and endothelial function. Current research projects include investigating the effect of ageing on the cardiovascular system, the link between inflammation and arterial function, and the effect of novel nitric oxide donors on pre-eclampsia. He is also involved in a number of large collaborative studies including the CLEAREST Study, Caerphilly Heart Study, ENIGMA Study and Whitehall II. In addition to his role with the OTR, he is also the Director of the Cambridge University Health Partners Clinical Trials Unit, which works with principal investigators to develop and deliver world-class clinical trials of all phases. Email:


Professor Patrick Maxwell
Prof Maxwell is Regius Professor of Physic and Head of the Clinical School. This is how he explains his research in Plain English: "Our bodies have careful controls in place to determine how cells react to oxygen deprivation or hypoxia. If oxygen levels are too low, a tissue must quickly respond by changing its behaviour, such as changing which fuel it uses or growing more blood vessels. This is mediated by turning genes on and off. We study the control of this response to oxygen by master regulators called the ‘hypoxia-inducible factors’. In particular, we focus on how these factors are themselves kept under tight control, their importance in oxygen sensing during development and in the immune system, as well as how they can cause specific types of kidney cancers." Email:


Professor Andy Neely
Prof Neely is Pro-Vice-Chancellor for Enterprise and Business Relations at the University of Cambridge and former Head of the Institute for Manufacturing (IfM). He is a Fellow of Sidney Sussex College and Director of the Centre for Digital Built Britain and Founding Director of the Cambridge Service Alliance. He is widely recognised for his work on the servitisation of manufacturing, as well as his work on performance measurement and management. Previously he has held appointments at Cranfield University, London Business School, Cambridge University, where he was a Fellow of Churchill College, Nottingham University, where he completed his PhD and British Aerospace. He was Deputy Director of AIM Research – the UK’s management research initiative – from 2003 until 2012 and was elected a Fellow of the Sunningdale Institute in 2005, a Fellow of the British Academy of Management in 2007, a Fellow of the Academy of Social Sciences in 2008, a Fellow of the European Operations Management Association in 2009 and a Fellow of the Royal Academy of Engineering in 2018. Email:


Malcolm Lowe-Lauri CBE
Mr Lowe-Lauri is the Executive Director of Cambridge University Health Partners. He joined the organisation in August 2016, following almost four years in his role as Executive Director - Health, Ageing and Human Services at KPMG Australia and as a member of the Global KPMG Centre of Excellence. Before joining KPMG, Malcolm had a 32-year career in the NHS where he held a number of leadership roles including Chief Executive Officer at University Hospitals Leicester NHS Trust and Chief Executive Officer at Kings College Hospital. From 2000-2012, Malcolm worked as a commissioner of a number of NHS Research & Development Programmes and from 2006-12 he was a member of the NIHR Advisory Board. He was also recently made a new Fellow in Health Management at the Judge's Centre for Health Leadership and Enterprise.


Prof John Bradley
Prof Bradley is the Director of the NIHR Cambridge Biomedical Research Centre. His team aims to understand the mechanisms through which alterations in vascular cell function contribute to vascular disease and transplant rejection. They focus on the role of tumour necrosis factor (TNF) in renal and cardiovascular disease, and how the two distinct receptors for TNF are independently regulated and mediate different cellular responses. Email: